특허 의약품 시장 : 제형별, 적응증별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

Patented Drugs Market By Dosage Form, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,917,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,264,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

특허 의약품 시장은 2022년 8,145억 달러로 평가되었고, 2023년부터 2032년까지 연평균 복합 성장률(CAGR) 6%로 성장하여 2032년에는 1조 4,565억 달러에 달할 것으로 추정됩니다.

신약 개발을 위한 연구 활동 증가, 생명공학 및 3D 모델링의 발전, 만성 질환을 앓고 있는 인구 증가가 특허 의약품 시장의 성장을 주도하고 있습니다. 연구자들은 다양한 질병 메커니즘, 분자 경로 및 약물 표적을 탐색하여 치료 개입의 잠재적 영역을 식별하고 있습니다. 이는 신약 개발의 기회를 창출하고 특허 의약품 시장의 성장을 가속하고 있습니다. 또한 심혈관 질환, 암, 당뇨병, 호흡기 질환, 신경 질환 등 만성 질환의 유병률은 세계적으로 꾸준히 증가하고 있습니다. 예를 들어, 2021년 미국암협회(ACS)는 미국에서 약 190만 명의 암 환자가 새로 진단될 것으로 추정하고 있습니다. 암에 대한 특허 의약품으로는 아바스틴, 키프러스, 이브란스 등이 있습니다. 이러한 만성 질환 증가는 효과적인 치료법과 관리 전략에 대한 수요 증가로 이어져 특허 의약품 시장의 성장을 주도하고 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 시장에 대한 COVID-19의 영향 분석

제4장 특허 의약품 시장 : 제형별

• 개요
• 고형 의약품
• 액체 의약품
• 기타

제5장 특허 의약품 시장 : 적응증별

• 개요
• 심혈관질환
• 암
• 자가면역질환
• 기타

제6장 특허 의약품 시장 : 유통 채널별

• 개요
• 병원 약국
• 드럭스토어 및 소매 약국
• 온라인 약국

제7장 특허 의약품 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카/중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• AbbVie Inc.
• Amgen Inc.
• Pfizer Inc.
• Novartis AG
• AstraZeneca plc
• Bayer AG
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Biogen
• Astellas Pharma Inc.

LSH

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Patented Drugs Market," The patented drugs market was valued at $814.5 billion in 2022, and is estimated to reach $1,456.5 billion by 2032, growing at a CAGR of 6% from 2023 to 2032.

The patented drugs market growth is driven by increase in the number of research activities for development of new drugs, advancement in biotechnology and 3D modeling, and rise in people suffering from chronic diseases. Researchers explore various disease mechanisms, molecular pathways, and drug targets to identify potential areas for therapeutic intervention. This creates opportunities for the development of new drugs which drives the growth of patented drugs market. Furthermore, the prevalence of chronic diseases, such as cardiovascular diseases, cancer, diabetes, respiratory disorders, and neurological conditions, has been steadily rising globally. For instance, in 2021 American Cancer Society (ACS), estimated that about 1.9 million new cancer cases were diagnosed in the U.S. The available patented drugs for cancer include Avastin, KYPROLIS, IBRANCE, and others. This rise in chronic diseases has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the patented drugs market.

In addition, the availability of robust regulatory authorities such as U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) determines the drug approval process and grant market exclusivity to pharmaceuticals. This exclusivity period provide advantages for pharmaceutical companies, enabling them to recover their investment and generate revenue from patented drugs. Furthermore, increase in number of patent application filing in 2022 further boost the growth of the patented drugs market. For instance, in 2022, European Patent Office (EPO), received a total of 193,460 applications. It was also reported that patent activity in pharmaceuticals increased by 1% as compared to 2021.

However, entry of generic versions of the drug at lower prices after patent expiration limit the growth of the patented drugs market. The availability of cheaper alternatives may impact the demand for patented drugs. Furthermore, high costs associated with new drug development is financially challenging for pharmaceutical companies and limit their ability to invest in innovation and develop new patented drugs thereby impacting the market growth. On the other hand, surge in technological advancements, such as precision medicine, genomics, proteomics, and targeted therapies, are revolutionizing drug discovery and development. These advancements enable the development of more effective and patented drugs during the forecast period.

The patented drugs market is segmented on the basis of dosage form, indication, distribution channel, and region. On the basis of dosage form, the market is classified into solid drug product, liquid drug product, and others. Others segments include semi-solid drug and gaseous drug. As per indication, the market is categorized into cardiovascular diseases, cancer, autoimmune diseases, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global patented drugs market are AbbVie Inc., Amgen Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bayer AG, Johnson & Johnson, F. Hoffmann-La Roche AG, Astellas Pharma Inc., and Biogen. Key players operating in the market have adopted patent and patent extension as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the patented drugs market analysis from 2022 to 2032 to identify the prevailing patented drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the patented drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global patented drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Distribution Channel

• Hospital Pharmacies
• Drug Store and Retail Pharmacies
• Online Pharmacies

By Dosage Form

• Solid Drug Product
• Liquid Drug Product
• Others

By Indication

• Cardiovascular Diseases
• Cancer
• Autoimmune Diseases
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Amgen Inc.
• Pfizer Inc.
• AstraZeneca plc
• Bayer AG
• Biogen
• Johnson & Johnson
• Astellas Pharma Inc.
• F. Hoffmann-La Roche AG
• Novartis AG
• AbbVie Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in investment in research and development activities
    • 3.4.1.2. Surge in disease burden

• 3.4.2. Restraints
  • 3.4.2.1. High cost of patented drugs

• 3.4.3. Opportunities
  • 3.4.3.1. Strong intellectual property rights

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PATENTED DRUGS MARKET, BY DOSAGE FORM

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Solid Drug Product
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Liquid Drug Product
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: PATENTED DRUGS MARKET, BY INDICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Cardiovascular Diseases
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Cancer
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Autoimmune Diseases
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: PATENTED DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Store and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Pharmacies
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: PATENTED DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Dosage Form
  • 7.2.3. Market size and forecast, by Indication
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Dosage Form
    • 7.2.5.1.3. Market size and forecast, by Indication
    • 7.2.5.1.4. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Dosage Form
    • 7.2.5.2.3. Market size and forecast, by Indication
    • 7.2.5.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Dosage Form
    • 7.2.5.3.3. Market size and forecast, by Indication
    • 7.2.5.3.4. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Dosage Form
  • 7.3.3. Market size and forecast, by Indication
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Dosage Form
    • 7.3.5.1.3. Market size and forecast, by Indication
    • 7.3.5.1.4. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Dosage Form
    • 7.3.5.2.3. Market size and forecast, by Indication
    • 7.3.5.2.4. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Dosage Form
    • 7.3.5.3.3. Market size and forecast, by Indication
    • 7.3.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Dosage Form
    • 7.3.5.4.3. Market size and forecast, by Indication
    • 7.3.5.4.4. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Dosage Form
    • 7.3.5.5.3. Market size and forecast, by Indication
    • 7.3.5.5.4. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Dosage Form
    • 7.3.5.6.3. Market size and forecast, by Indication
    • 7.3.5.6.4. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Dosage Form
  • 7.4.3. Market size and forecast, by Indication
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Dosage Form
    • 7.4.5.1.3. Market size and forecast, by Indication
    • 7.4.5.1.4. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Dosage Form
    • 7.4.5.2.3. Market size and forecast, by Indication
    • 7.4.5.2.4. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Dosage Form
    • 7.4.5.3.3. Market size and forecast, by Indication
    • 7.4.5.3.4. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Dosage Form
    • 7.4.5.4.3. Market size and forecast, by Indication
    • 7.4.5.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Dosage Form
    • 7.4.5.5.3. Market size and forecast, by Indication
    • 7.4.5.5.4. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Dosage Form
    • 7.4.5.6.3. Market size and forecast, by Indication
    • 7.4.5.6.4. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Dosage Form
  • 7.5.3. Market size and forecast, by Indication
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Dosage Form
    • 7.5.5.1.3. Market size and forecast, by Indication
    • 7.5.5.1.4. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Dosage Form
    • 7.5.5.2.3. Market size and forecast, by Indication
    • 7.5.5.2.4. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Dosage Form
    • 7.5.5.3.3. Market size and forecast, by Indication
    • 7.5.5.3.4. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Dosage Form
    • 7.5.5.4.3. Market size and forecast, by Indication
    • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AbbVie Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Amgen Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Pfizer Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Novartis AG
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. AstraZeneca plc
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Bayer AG
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
• 9.7. Johnson & Johnson
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. F. Hoffmann-La Roche AG
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Biogen
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Astellas Pharma Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance

관련자료